2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete data
2008
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcohol Clinical And Experimental Research 2008, 32: 1159-1166. PMID: 18537939, PMCID: PMC2950972, DOI: 10.1111/j.1530-0277.2008.00735.x.Peer-Reviewed Original ResearchConceptsOpioid receptor geneSingle nucleotide polymorphismsTherapeutic effectReceptor geneHeavy drinkingOpioid antagonist nalmefenePlacebo-controlled trialKappa-opioid receptorsNaltrexone treatment responseHeavy drinking daysReceptor gene polymorphismsOpioid receptor gene polymorphismsAsn40Asp polymorphismNalmefene treatmentPolymorphic variationAntagonist treatmentMedication responseTreatment responsePharmacogenetic analysisReceptor gene variationDrinking daysNalmefeneGene polymorphismsHeavy drinkersConflicting results
1994
Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine. JAMA Psychiatry 1994, 51: 912-917. PMID: 7944879, DOI: 10.1001/archpsyc.1994.03950110072009.Peer-Reviewed Original ResearchConceptsClinical responseTherapeutic effectAtypical antipsychotic drug clozapineClozapine's therapeutic effectsTreatment-refractory schizophreniaPathophysiology of schizophreniaAntipsychotic drug clozapineD4 dopamine receptorsDRD4 allelesPutative third cytoplasmic loopSchizoaffective patientsTherapeutic responseTherapy variesDopamine receptorsSchizoaffective subjectsTreatment responseThird cytoplasmic loopDrug clozapineClozapineDopamine receptor geneSchizoaffective disorderD4 receptorsPolymerase chain reaction amplificationReceptor allelesChain reaction amplification